



012604

23026 U.S. PTO

Docket No.: PA-0024-1 CON

Certificate of Mailing

"Express Mail" mailing label number EV 309 715 705 US I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated and is addressed to: Mail Stop: Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on January 26, 2004.

By:

Printed: Nancy Ramos

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

REQUEST FOR FILING A PATENT APPLICATION UNDER 37 CFR 1.53(b)

Commissioner for Patents
Box Patent Application
Alexandria, Virginia 22313-1450
Dear Sir:

This is a request for filing a **CONTINUATION** application under 37 CFR 1.53(b) of pending prior application Serial No. **09/566,521**, filed on **May 5, 2000**, entitled GENES EXPRESSED IN ALZHEIMER'S DISEASE, which is being incorporated herein by reference.

X Enclosed is a specification corresponding to the prior application, U. S. Application Serial No. **09/566,521**, filed on **May 5, 2000**, including the oath or declaration as originally signed. The specification does not contain any subject matter that would have been new matter in the prior application.

X With regard to the requirement of 37 CFR 1.821(e) which requires that a copy of the Sequence Listing in computer readable form (CRF) be submitted, Applicants state that the paper copy of the Sequence Listing for the instant continuation application is identical with the computer readable form filed with Serial No. **09/566,521**, filed **May 5, 2000**, to which priority is claimed. In accordance with 37 C.F.R. §1.821(e), please use the computer readable form filed with U.S. Application Serial No. **09/566,521** as the computer readable form for the instant continuation application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application.

Amend the specification by inserting after the title: "This application is a application of U.S. application serial number , filed , all of which applications and patents are hereby incorporated herein by reference."

Cancel in this application original claims [**CANCELED CLAIMS**] before calculating the filing fee, without prejudice or disclaimer. Applicants submit that these claims were included in the application as filed in the interest of providing notice to the public of certain specific subject matter intended to be claimed, and are being canceled at this time in the interest of reducing filing costs. Applicants expressly state that these claims are not being canceled for reasons related to patentability, and are in fact fully supported by the specification as filed. Applicants expressly reserve the right to reinstate these claims or to add other claims during prosecution of this application or a continuation or divisional application. Applicants expressly do not disclaim the subject matter of any invention disclosed herein which is not set forth in the instantly filed claims.

X The inventor(s) of the invention being claimed in this application is (are): Jeanne F. Loring, Debora W. Tingley, Carla M. Edwards.

X The prior application is assigned of record to Incyte Corporation, formerly known as Incyte Genomics, Inc., also formerly known as Incyte Pharmaceuticals, Inc., recorded on **August 28, 2000**, at reel /frame 011126/0856.

22141 U.S. PTO
10/765700

012604

X The power of attorney of the prior application is to:

Adam Warwick Bell
Lucy J. Billings
Michael C. Cerrone
Diana Hamlet-Cox
Matthew R. Kaser
Lynn E. Murry
Susan K. Sather
David G. Streeter
Christopher Turner
Peng Ben Wang

Reg. No. 43,490
Reg. No. 36,749
Reg. No. 39,132
Reg. No. 33,302
Reg. No. 44,817
Reg. No. 42,918
Reg. No. 44,316
Reg. No. 43,168
Reg. No. 45,167
Reg. No. 41,420

X The invention was not made by an agency of the United States Government or under a contract with an agency of the United States Government.

ENCLOSURES

- X Application Data Sheet (ADS) (pp.).
- X Blanket Exemption from Requirements Under § 42 U.S.C. 2182 Letter (1 pg.).
- X In accordance with 37 CFR 1.63(d), a copy of the originally signed declaration showing applicant's/applicants' signature(s) as filed on (pp.).
- X Submission of Formal Drawings (pp.); and Sheets of Formal Drawings, including Figure 1.
- X Information Disclosure Statement (2 pp.); and List of References Cited PTO-1449 (2 pp.).
- Copy of previously submitted Certification under 37 C.F.R. §3.73(b), Revocation of Power of Attorney and Appointment of New Attorneys (2 pp.).
- X A new Certification under 37 C.F.R. §3.73(b), Revocation of Power of Attorney and Appointment of New Attorneys (2 pp.).
- Petition for Extension of Time under 37 C.F.R. § 1.136(b) (1 pg.).
- Preliminary Amendment (pp.)
- X Submission under 37 C.F.R. § 1.821-1.825 Sequence Listing (1 pg.).
- (One) 1 Substitute CRF diskette containing the sequence listing.
- Other:

CLAIMS AS FILED

Claims	Number Filed	Minus	Number Extra	Other Than Small Entity Rate	Fee	Basic Fee	
						\$	770.00
Total Claims	19	-20	0	x \$18		\$	0
Indep. Claims	2	-3	0	x \$86		\$	0
Multiple Dependent Claim(s), if any				+ \$290		\$	0
Filing Fee:						\$	770.00

FEE CALCULATION AND METHOD OF PAYMENT

The Fee has been calculated as follows:

<input checked="" type="checkbox"/>	Fee for filing a Continuation Application Under 37 C.F.R. 1.16 (a):	\$	<u>770.00</u>
<input type="checkbox"/>	Fee for Petition for Extension of Time Under 37 C.F.R. § 1.17(a) <input type="text"/> Mo(s).:	\$	<input type="text"/>
<input checked="" type="checkbox"/>	Please charge Deposit Account No. 09-0108 in the amount of :	\$	<u>770.00</u>

Applicants hereby authorize the Commissioner to treat any concurrent or future reply in this application that requires a petition for an extension of time under 37 C.F.R. § 1.136(a) to be timely, as incorporating a petition for extension of time for the appropriate length of time; and to charge all required fees, including fees under 37 C.F.R. §§ 1.16, 1.17, and all required extension of time fees, or to credit any overpayment, to Deposit Account **09-0108**. **This sheet is enclosed in duplicate.**

CORRESPONDENCE ADDRESS
(Customer No. 27904)

INCYTE CORPORATION
LEGAL DEPARTMENT
3160 Porter Drive
Palo Alto, California 94304

Phone: (650) 855-0555
Fax: (650) 845-4166 or
(650) 849-8886

Date:

January 24, 2014

By:

David G. Streeter

David G. Streeter, Ph.D.

Reg. No. 43,168

Direct Dial Telephone: (650) 845-5741

☐ Inventor(s).

☐ Assignee of complete interest.

☒ Attorney or Agent of record.

☐ Filed under 37 C.F.R. § 1.34(a), with Limited Recognition under 37 C.F.R. § 10.9 (b).

☐ Filed under 37 C.F.R. § 1.34(a) Registration number if acting under 37 C.F.R. § 1.34(a).

Certificate of Mailing

"Certificate of Express Mail" mailing label number EV 309 715 705 US I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Mail Stop, Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on January 26, 2004.
By: Nancy Ramos Printed: Nancy Ramos

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Loring et al.

Title: GENES EXPRESSED IN ALZHEIMER'S DISEASE

Serial No.: 09/566,521

Filing Date: Herewith

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

Mail Stop: Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUBMISSION OF FORMAL DRAWINGS

Sir:

Transmitted herewith is Figure 1, as one (1) sheet of formal drawings for this application. Each sheet of drawing indicates the identifying indicia suggested in 37 CFR Section 1.84(c) on the front side of the drawings.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. 09-0108.

If there are any questions regarding the above, the Examiner is invited to call the undersigned.

Respectfully submitted,

INCYTE CORPORATION

Date:

January 26, 2004

David G. Streeter

David G. Streeter, Ph.D.

Reg. No. 43,168

Direct Dial Telephone: (650) 845-5741

Customer No.: 27904
3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166